Gain Therapeutics Files 8-K on Shareholder Vote
Ticker: GANX · Form: 8-K · Filed: Jun 25, 2024 · CIK: 1819411
| Field | Detail |
|---|---|
| Company | Gain Therapeutics, Inc. (GANX) |
| Form Type | 8-K |
| Filed Date | Jun 25, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
TL;DR
Gain Therapeutics held a shareholder vote on 6/24, details to follow.
AI Summary
Gain Therapeutics, Inc. filed an 8-K on June 25, 2024, reporting on matters submitted to a vote of its security holders on June 24, 2024. The filing does not disclose the specific proposals voted upon or the outcomes.
Why It Matters
This filing indicates that Gain Therapeutics held a shareholder vote, which could have implications for corporate governance and future strategic decisions.
Risk Assessment
Risk Level: low — The filing is procedural and does not contain new financial or operational information that would immediately impact the company's risk profile.
Key Players & Entities
- Gain Therapeutics, Inc. (company) — Registrant
- June 24, 2024 (date) — Date of earliest event reported
- June 25, 2024 (date) — Date of report
FAQ
What specific matters were submitted for a vote by Gain Therapeutics' security holders?
The filing does not specify the exact proposals that were put to a vote.
When did the shareholder meeting or vote take place?
The earliest event reported, which is the date of the vote, was June 24, 2024.
What is the primary purpose of this 8-K filing?
The primary purpose is to report on matters submitted to a vote of security holders.
Where is Gain Therapeutics, Inc. headquartered?
Gain Therapeutics, Inc. is headquartered in Bethesda, Maryland.
What is the SEC file number for Gain Therapeutics, Inc.?
The SEC file number for Gain Therapeutics, Inc. is 001-40237.
Filing Stats: 569 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2024-06-25 17:20:16
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 GANX The Nasdaq Stock Market LLC It
Filing Documents
- tm2418205d1_8k.htm (8-K) — 34KB
- 0001104659-24-074822.txt ( ) — 205KB
- ganx-20240624.xsd (EX-101.SCH) — 3KB
- ganx-20240624_lab.xml (EX-101.LAB) — 33KB
- ganx-20240624_pre.xml (EX-101.PRE) — 22KB
- tm2418205d1_8k_htm.xml (XML) — 4KB
07
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 24, 2024, Gain Therapeutics, Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting"), at which a quorum was present. The matters voted on at the Annual Meeting were: (1) the election of eight directors and (2) the ratification of the appointment of Ernst & Young AG as the Company's independent registered public accounting firm. The final voting results were as follows: 1. The election of Matthias Alder, Dov Goldstein, M.D., Hans Peter Hasler, Khalid Islam, Ph.D, Gwen Melincoff, Claude Nicaise, M.D., Eric I. Richman, and Jeffrey Riley as directors to hold office for a term of one year, until their successors are duly elected and qualified or they are otherwise unable to complete their respective terms. The votes were cast for this matter were as follows: Nominee For Withheld Broker Non-Votes Matthias Alder 4,708,186 2,100,956 5,183,098 Dov Goldstein, M.D. 6,520,571 288,571 5,183,098 Hans Peter Hasler 4,308,578 2,500,564 5,183,098 Khalid Islam, Ph.D. 4,783,551 2,025,591 5,183,098 Gwen Melincoff 4,766,864 2,042,278 5,183,098 Claude Nicaise, M.D. 4,727,288 2,081,854 5,183,098 Eric I. Richman 6,581,651 227,491 5,183,098 Jeffrey Riley 4,733,278 2,075,864 5,183,098 2. The proposal to ratify the appointment of Ernst & Young AG as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was approved based upon the following votes: For Against Abstain 11,836,784 119,833 35,623 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GAIN THERAPEUTICS, INC. Date: June 25, 2024 By: /s/ Gene Mack Name: Gene Mack Title: Chief Financial Officer